SG

Sevgi Gurkan

Founder and CEO, Perfuse Therapeutics, Inc. / Venture Partner at OrbiMed

San Francisco Bay Area

Investor
VC

Invests in

Stages:

Series A
Seed

  • Min Investment:

    $1,000,000.00

  • Max Investment:

    $75,000,000.00

  • Target Investment:

    $4,000,000.00

Skills

Board Level
Board Administration
Medical Education
Board Certified
Clinical Research
Medicine
Pediatrics
Medical Research
Clinical Trials
Research
Healthcare
Hospitals
Immunology
Translational Research
Treatment
In Vitro
In Vivo
Protocol
Laboratory
Nephrology

Education

Lists including Sevgi

AT
AS
AT
AH

All Series A Investors

14752 people

AM
AT
AS
AR

All Seed Investors

19695 people

Work Experience

CP
Corteria Pharmaceuticals

2023

  • Member Board of Directors

    2023

PT
Perfuse Therapeutics

2018

  • Founder, President and CEO

    2018

O
OrbiMed

2018

  • Venture Partner

    2018

M
Merck

2014 - 2018

  • Group Lead / Director / Discovery Biology South San Francisco

    2016 - 2018

  • Medical Director / Early Clinical Development

    2014 - 2016

RU
Rutgers University

2008 - 2016

  • Associate Professor/Pediatric Nephrology

    2008 - 2016

Robert Wood Johnson University Hospital

2013 - 2014

  • Director, Pediatric Kidney Transplant Center

    2013 - 2014

    Determine and update pediatric kidney transplant immunosuppressive protocol Treat all pediatric kidney transplant patients pre- and post-transplant

Child Health Institute of New Jersey

2010 - 2014

  • Physician Scientist

    2010 - 2014

    Laboratory focus on immunological mechanisms of podocyte injury